Real-world clinical outcomes among patients with EGFR-mutated (Ex19del/L858R) metastatic NSCLC treated at City of Hope with osimertinib monotherapy by TP53 alteration status.
703 Background: Epidermal growth factor receptor mutations (EGFRm) occur in ~15% of non-small cell lung cancer (NSCLC) cases, with exon 19 deletions (Ex19del) and exon 21 L858R substitutions (L858R) comprising 85-90%. Osimertinib (Osi) monotherapy (mono) is one of the first-line (1L) treatment options, while mo...